Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Eli Lilly and Company |
---|---|
Information provided by: | Eli Lilly and Company |
ClinicalTrials.gov Identifier: | NCT00034801 |
This is a research study comparing the safety and efficacy of two active study medications
Condition | Intervention | Phase |
---|---|---|
Depression Schizophrenia Schizoaffective Disorder |
Drug: olanzapine Drug: ziprasidone |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Controlled Trial of Olanzapine Versus Active Comparator in the Treatment of Schizophrenic and Schizoaffective Subjects With Comorbid Depression |
Ages Eligible for Study: | 18 Years to 60 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 5529, F1D-US-HGJU |
Study First Received: | May 2, 2002 |
Last Updated: | July 18, 2006 |
ClinicalTrials.gov Identifier: | NCT00034801 |
Health Authority: | United States: Food and Drug Administration |
Depression Comorbid Depression Schizophrenia Schizoaffective Disorder |
Schizophrenia Dopamine Depression Mental Disorders Olanzapine Mood Disorders |
Psychotic Disorders Ziprasidone Depressive Disorder Serotonin Schizophrenia and Disorders with Psychotic Features Behavioral Symptoms |
Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Tranquilizing Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Gastrointestinal Agents Psychotropic Drugs Antiemetics Central Nervous System Depressants Dopamine Antagonists |
Antipsychotic Agents Serotonin Uptake Inhibitors Pharmacologic Actions Serotonin Antagonists Serotonin Agents Autonomic Agents Therapeutic Uses Dopamine Agents Peripheral Nervous System Agents Central Nervous System Agents |